Maravai LifeSciences Holdings Inc. Class A Common Stock vs Vistra Corp — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Vistra Corp trades at $146.98 (market cap $50.95B). The key difference: Vistra Corp is far larger — about 52.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Vistra Corp pays a 0.61% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Vistra Corp for 33 Days on average.
| MRVI | VST | |
|---|---|---|
Market Cap | $977.37M | $50.95B |
Volume | 2,742,564 | 7,315,402 |
Sector | Health | Utilities |
52-Week High | $9.00 | $210.85 |
52-Week Low | $2.83 | $134.71 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $1.08B | $72.88B |
Dividend Yield | — | 0.61% |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Vistra Corp. (VST) trades at $162.36, up 2.68% today, reflecting strong momentum amid bullish technical signals and positive analyst sentiment. The stock shows robust fundamentals with a 75.73% ROE and 11.55% net income margin for 2026, alongside recent catalysts including a $4.2 billion US loan for nuclear expansion and a 20-year power deal with New Era Energy. Earnings have been volatile, with a Q1 2026 beat but Q2 and Q4 2025 misses, while cash flow trends improved significantly in 2026.
Outlook remains positive given Wall Street's consensus $215.23 price target and 91.3% buy ratings, driven by AI-driven power demand and nuclear scale advantages. Key risks include execution on growth initiatives, debt levels, and energy market volatility. The stock presents a compelling opportunity if the company capitalizes on data center electricity scarcity.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →